Germany - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), announced today that the company is scheduled to attend the J.P. Morgan Healthcare Conference.

38th Annual JP Morgan Healthcare Conference - Biotech Showcase

Date: January 13-16, 2020

Venue: San Francisco, USA

Participant: Dr. Ulrich Dauer, CEO

Contact:

Joanne Tudorica

Tel: +49 176 2103 7191

Email: Trophic@vivoryon.com

About Vivoryon Therapeutics AG

With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, PQ912, in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications.

Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

(C) 2020 Electronic News Publishing, source ENP Newswire